Immunogenicity and Safety of 2 Schedules of ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

November 30, 2005

Study Completion Date

September 30, 2006

Conditions
HIV Infection
Interventions
BIOLOGICAL

one injection of vCP1452 at W0, W4, W8 and W20

BIOLOGICAL

one injection of vCP1452 at W4, W8 and W20

BIOLOGICAL

one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20

Trial Locations (5)

60590

Klinikum der Johann Nolfgang Goethe Universitat Zentrum des Innerin Medizin, Frankfurt am Main

60611

Northwestern University Medical School, Chicago

75013

Service des maladies infectieuses et tropicales, Hopital Pitié-Salpétrière, Pavillon Laveran, Paris

08916

Fundacio Irsi Caixa Retrovirology Laboratory, Hospital Universitari Germans, Badalona

08036

Servicios de Infecciosos, Hospital y clinic Provincial, Barcelona

All Listed Sponsors
lead

Objectif Recherche Vaccins SIDA

OTHER

NCT00219362 - Immunogenicity and Safety of 2 Schedules of ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients | Biotech Hunter | Biotech Hunter